Mark Wainberg

Summary

Affiliation: McGill University
Country: Canada

Publications

  1. ncbi Novel therapeutic strategies targeting HIV integrase
    Peter K Quashie
    McGill University AIDS Centre, Lady Davis Institute, Montreal, Canada
    BMC Med 10:34. 2012
  2. ncbi The viral protein Tat can inhibit the establishment of HIV-1 latency
    Daniel A Donahue
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    J Virol 86:3253-63. 2012
  3. ncbi Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir
    Peter K Quashie
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
    J Virol 86:2696-705. 2012
  4. ncbi The role of unintegrated DNA in HIV infection
    Richard D Sloan
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada
    Retrovirology 8:52. 2011
  5. ncbi Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably?
    Rodney S Russell
    McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec, H3T 1E2, Canada
    Retrovirology 1:23. 2004
  6. ncbi New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and flu
    Anne Gatignol
    Lady Davis Institute for Medical Research, and Department of Medicine, Microbiology and Immunology, McGill University, Montreal, Quebec, Canada
    Retrovirology 4:8. 2007
  7. ncbi Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection
    Guido van Marle
    Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
    Retrovirology 7:74. 2010
  8. ncbi Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes
    Richard D Sloan
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada
    Retrovirology 7:44. 2010
  9. ncbi PRMT6 diminishes HIV-1 Rev binding to and export of viral RNA
    Cédric F Invernizzi
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Sir Mortimer B, Davis Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    Retrovirology 3:93. 2006
  10. ncbi Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance
    Hong Tao Xu
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec H3T1E2, Canada
    Retrovirology 6:14. 2009

Research Grants

  1. DELETION MUTAGENESIS WITHIN NONCODING SEGMENTS OF HIV1
    Mark Wainberg; Fiscal Year: 2001

Detail Information

Publications104 found, 100 shown here

  1. ncbi Novel therapeutic strategies targeting HIV integrase
    Peter K Quashie
    McGill University AIDS Centre, Lady Davis Institute, Montreal, Canada
    BMC Med 10:34. 2012
    ..This review considers the history of the clinical development of HIV integrase inhibitors, the development of antiviral drug resistance and the need for new antiviral compounds...
  2. ncbi The viral protein Tat can inhibit the establishment of HIV-1 latency
    Daniel A Donahue
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    J Virol 86:3253-63. 2012
    ....
  3. ncbi Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir
    Peter K Quashie
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
    J Virol 86:2696-705. 2012
    ..Structural modeling suggested and in vitro IN-DNA binding assays show that the R263K mutation affects IN-DNA interactions...
  4. ncbi The role of unintegrated DNA in HIV infection
    Richard D Sloan
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada
    Retrovirology 8:52. 2011
    ..This review focuses on the role of unintegrated DNA in HIV infection and additionally considers the potential implications for antiviral therapy...
  5. ncbi Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably?
    Rodney S Russell
    McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec, H3T 1E2, Canada
    Retrovirology 1:23. 2004
    ....
  6. ncbi New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and flu
    Anne Gatignol
    Lady Davis Institute for Medical Research, and Department of Medicine, Microbiology and Immunology, McGill University, Montreal, Quebec, Canada
    Retrovirology 4:8. 2007
    ..Aspects of viral structure, virus-host interactions, antiviral defenses, drugs and vaccinations, and epidemiological aspects were discussed for HIV and HCV. Old and recent data on the flu epidemics ended this meeting...
  7. ncbi Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection
    Guido van Marle
    Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
    Retrovirology 7:74. 2010
    ..It serves as a viral reservoir and host-pathogen interface in infection. This study examined whether different parts of the gut and peripheral blood lymphocytes (PBL) contain different drug-resistant HIV-1 variants...
  8. ncbi Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes
    Richard D Sloan
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada
    Retrovirology 7:44. 2010
    ..Infected cells bearing unintegrated DNA were assayed by flow cytometry in the GFP reporter cell line, Rev-CEM, for cell surface levels of CD4, CXCR4 and CCR5...
  9. ncbi PRMT6 diminishes HIV-1 Rev binding to and export of viral RNA
    Cédric F Invernizzi
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Sir Mortimer B, Davis Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    Retrovirology 3:93. 2006
    ..Since Tat is known to be asymmetrically arginine dimethylated by protein arginine methyltransferase 6 (PRMT6) in its arginine rich motif, we investigated whether the Rev protein could act as a substrate for this enzyme...
  10. ncbi Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance
    Hong Tao Xu
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec H3T1E2, Canada
    Retrovirology 6:14. 2009
    ..We investigated the effects of mutations K65R and K65R plus M184V on enzymatic function and mechanisms of drug resistance in subtype C reverse transcriptase (RT)...
  11. ncbi Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C
    Hong Tao Xu
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
    Retrovirology 7:80. 2010
    ....
  12. ncbi Impact of the 16th International Conference on AIDS: can these conferences lead to policy change?
    Helene Gayle
    CARE USA, Atlanta, GA 30303, USA
    Retrovirology 4:13. 2007
    ..It is vital that scientists and policy-makers continue to be able to interact at these meetings as part of global efforts to combat the HIV epidemic...
  13. ncbi The XVI International Conference on AIDS: the place to be!
    Mark A Wainberg
    Retrovirology 3:9. 2006
    ....
  14. ncbi Recovery of fitness of a live attenuated simian immunodeficiency virus through compensation in both the coding and non-coding regions of the viral genome
    James B Whitney
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada
    Retrovirology 4:44. 2007
    ..These findings indicate that viral reversion that overcomes a genetic bottleneck is not limited to a single pathway, and illustrates the remarkable adaptability of lentiviruses...
  15. ncbi Highly diversified multiply drug-resistant HIV-1 quasispecies in PBMCs: a case report
    Yudong Quan
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec, H3T 1E2, Canada
    Retrovirology 5:43. 2008
    ....
  16. ncbi Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes
    Tamara Bar-Magen
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada
    Retrovirology 6:103. 2009
    ..Due to high HIV variability, integrase inhibitor efficacy must be evaluated against a range of integrase enzymes from different subtypes...
  17. ncbi Impaired RNA incorporation and dimerization in live attenuated leader-variants of SIVmac239
    James B Whitney
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada
    Retrovirology 3:96. 2006
    ..We also assessed the impact of these deletions upon viral infectiousness, replication kinetics and gene expression in cell lines and monkey peripheral blood mononuclear cells (PBMC)...
  18. ncbi Tetherin restricts direct cell-to-cell infection of HIV-1
    Björn D Kuhl
    McGill University AIDS Center, Lady Davis Institute, Jewish General Hospital, Montreal, Canada
    Retrovirology 7:115. 2010
    ..Viral dissemination between T-cells can occur via cell-free transmission or the more efficient direct cell-to-cell route through lipid raft-rich virological synapses, to which tetherin localizes...
  19. ncbi Time for gender mainstreaming in editorial policies
    Shirin Heidari
    Journal of the International AIDS Society, 1216 Cointrin, Geneva, Switzerland
    J Int AIDS Soc 14:11. 2011
    ..Editors' associations could play an essential role in facilitating a transition to improved standard editorial policies...
  20. ncbi Journal of the International AIDS Society: an important step forward
    Mark A Wainberg
    International AIDS Society, Geneva, Switzerland
    J Int AIDS Soc 11:1. 2008
    ..ABSTRACT: This editorial welcomes readers to the launch of Journal of the International AIDS society...
  21. ncbi HIV-1 subtype distribution and the problem of drug resistance
    Mark A Wainberg
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    AIDS 18:S63-8. 2004
    ..This consideration notwithstanding, drug resistance is unlikely to become a more serious issue in developing than developed countries, and there is an urgency to make anti-HIV drugs available to all who are in need...
  22. ncbi The emergence of HIV resistance and new antiretrovirals: are we winning?
    Mark A Wainberg
    McGill University AIDS Centre, Jewish General Hospital, 3755 Chemin Cote Ste-Catherine, Montreal, Que, Canada H3T 1E2
    Drug Resist Updat 7:163-7. 2004
  23. ncbi The impact of the M184V substitution on drug resistance and viral fitness
    Mark A Wainberg
    McGill University AIDS Centre, 3755 Chemin de la Cote Ste Catherine, Montreal, Quebec H3T 1E2, Canada
    Expert Rev Anti Infect Ther 2:147-51. 2004
    ..Processivity of the reverse transcriptase enzyme may be affected by mutations such as M184V, and this may be a major determinant of viral replication fitness...
  24. ncbi Resistance issues with new nucleoside/nucleotide backbone options
    Mark A Wainberg
    McGill University AIDS Centre, Montreal, Canada
    J Acquir Immune Defic Syndr 37:S36-43. 2004
    ..This review summarizes the clinical implications of resistance profiles associated with new NRTI/NtRTI regimens in current use and in advanced clinical studies...
  25. ncbi HIV transmission should be decriminalized: HIV prevention programs depend on it
    Mark A Wainberg
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    Retrovirology 5:108. 2008
    ..In fact, however, people should understand that such legal action, and the willingness of the courts to hear these cases, will only weaken the global battle against HIV transmission...
  26. ncbi Benefits of an educational program for journalists on media coverage of HIV/AIDS in developing countries
    Jorge L Martinez-Cajas
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
    J Int AIDS Soc 11:2. 2008
    ..abstract:..
  27. ncbi Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection
    Mark A Wainberg
    McGill University AIDS Center, Lady Davis Institute Jewish General Hospital, Montreal, QC, Canada
    Antivir Ther 10:13-28. 2005
    ..The successful development of new NRTIs will depend upon a thorough appreciation of these many and complex issues, not only among those involved in the design of clinical studies, but also those contributing to their review and conduct...
  28. ncbi 25 years of HIV-1 research - progress and perspectives
    Mark A Wainberg
    McGill University AIDS Centre, Jewish General Hospital, chemin Cote Ste Catherine, Montreal, Quebec H3T 1E2, Canada
    BMC Med 6:31. 2008
    ..Here, we summarize, in brief, advances that have been achieved and provide some perspectives on future challenges...
  29. ncbi Perspectives on antiviral drug development
    Mark A Wainberg
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Canada
    Antiviral Res 81:1-5. 2009
    ..These topics will all play a pivotal role in drug development and the management of viral infections in the years to come...
  30. ncbi Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine
    Michel Ntemgwa
    McGill University AIDS Centre, Jewish General Hospital, 3755 Cote Ste Catherine Rd, Montreal, Quebec, Canada H3T 1E2
    Antimicrob Agents Chemother 51:3861-9. 2007
    ....
  31. ncbi Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase
    Mark A Wainberg
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, , , Canada
    Antimicrob Agents Chemother 49:1671-8. 2005
  32. ncbi Review: immunologic response to protease inhibitor-based highly active antiretroviral therapy: a review
    Mark A Wainberg
    McGill University AIDS Center, Jewish General Hospital, Montreal, Quebec, Canada
    AIDS Patient Care STDS 21:609-20. 2007
    ..Further research is required to clarify the relative importance of these mechanisms and ways in which they might be enhanced...
  33. ncbi The role of Tat in HIV-1 replication: an activator and/or a suppressor?
    Chen Liang
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec, Canada H3T 1E2
    AIDS Rev 4:41-9. 2002
    ..This suppressor activity of Tat can restrict the premature reverse transcription of viral RNA in the cytoplasm and allows the viral genome to be packaged as intact RNA molecules...
  34. ncbi In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine
    Susan M Schader
    Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada
    Antimicrob Agents Chemother 56:751-6. 2012
    ....
  35. ncbi Transmission dynamics of the M184V drug resistance mutation in primary HIV infection
    Mark A Wainberg
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    J Antimicrob Chemother 66:2346-9. 2011
    ..M184V in HIV-1 reverse transcriptase is among the most common mutations in patients failing antiretroviral therapy but is found only rarely in cases of transmitted drug resistance...
  36. ncbi Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens
    Florence Doualla-Bell
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    J Int AIDS Soc 12:25. 2009
    ..abstract:..
  37. ncbi Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008)
    Jorge L Martinez-Cajas
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    J Int AIDS Soc 12:11. 2009
    ..Attention to newer drug combinations, as well as baseline genotyping of non-B isolates, in well-designed longitudinal studies with long duration of follow up are needed...
  38. ncbi Sequencing of therapy to avoid resistance and the need for new antiretroviral drugs in the treatment of HIV disease
    Mark A Wainberg
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Quebec, Canada
    Infect Disord Drug Targets 9:172-90. 2009
    ..The ability to sequence new therapies will be enhanced by availability of new antiretroviral drugs...
  39. ncbi Is there any hope for AIDS?
    Mark A Wainberg
    McGill University AIDS Centre, Lady Davis Institute, Sir Mortimer B Davis Jewish General Hospital, Montreal, Que
    Clin Invest Med 27:51-8. 2004
    ..There is an urgency to make anti-HIV drugs available to all who are in need, regardless of ability to pay...
  40. ncbi Lack of effect of recombinant human growth hormone on the in vitro activities of antiretroviral drugs against human immunodeficiency virus type 1
    Mark A Wainberg
    McGill AIDS Center, Jewish General Hospital, Lady Davis Institute, 3755 Cote St Catherine Rd, Montreal, Quebec H3T 1E2, Canada
    Antimicrob Agents Chemother 48:2337-40. 2004
    ..r-hGH had no significant effect on either viral replication or the 50% inhibitory concentrations of these compounds...
  41. ncbi Jean-Luc Darlix: Renaissance scientist and retrovirologist par excellence
    Mark A Wainberg
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    Retrovirology 8:59. 2011
    ..ABSTRACT: Jean-Luc Darlix was recently recognized with the first Retrovirology Lifetime Achievement Award on the occasion of his "retirement" symposium in Lyon...
  42. ncbi Effects of a single amino acid substitution within the p2 region of human immunodeficiency virus type 1 on packaging of spliced viral RNA
    Rodney S Russell
    McGill AIDS Centre, Lady Davis Institute-Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2
    J Virol 77:12986-95. 2003
    ..Taken together, our data demonstrate that selective packaging of viral genomic RNA is influenced by the MP2 mutation and that this represents a major mechanism for rescue of viruses containing the DeltaDIS deletion...
  43. ncbi Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression
    Marie Chloe Boulanger
    Terry Fox Molecular Oncology Group, Lady Davis Institute, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
    J Virol 79:124-31. 2005
    ..Our study demonstrates that arginine methylation of Tat negatively regulates its transactivation activity and that PRMT6 acts as a restriction factor for HIV replication...
  44. ncbi Transmission networks of drug resistance acquired in primary/early stage HIV infection
    Bluma G Brenner
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    AIDS 22:2509-15. 2008
    ..In Quebec, half of PHIs represent clustered transmission events. This study ascertained the cumulative implications of clustering on onward transmission of drug resistance...
  45. ncbi Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2
    Michel L Ntemgwa
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
    Antimicrob Agents Chemother 53:708-15. 2009
    ..These results underscore potential differences in emergent drug resistance pathways in HIV-1 and HIV-2 and show that polymorphisms may influence the development of the resistance pathways that are likely to emerge...
  46. ncbi Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat Interactions with both cyclin T1 and the Tat transactivation region
    Baode Xie
    McGill University AIDS Centre, Department of Medicine, Terry Fox Molecular Oncology Group, Lady Davis Institute, St Mortimer B Davis Jewish General Hospital, 3755 Cote Ste Catherine Rd, Montreal, Quebec H3T 1E2, Canada
    J Virol 81:4226-34. 2007
    ..Finding a way of inhibiting or stimulating PRMT6 activity might help to drive quiescently infected cells out of latency or combat HIV-1 replication, respectively...
  47. ncbi Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor
    Tamara Bar-Magen
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    J Virol 84:9210-6. 2010
    ....
  48. ncbi Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance
    Hugues Loemba
    McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, 3755 Cote Ste-Catherine Road, Montreal, Quebec, Canada H3T 1E2
    Antiviral Res 56:129-42. 2002
    ..Further characterization of predicted CTL and T-helper anchor motifs and ARV-induced mutations in HIV-1 non-B subtype RTs is warranted...
  49. ncbi Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT
    Hugues Loemba
    McGill University AIDS Centre, Lady Davis Institute-Jewish General Hospital, Montreal, Quebec, Canada
    Antimicrob Agents Chemother 46:2087-94. 2002
    ..These findings suggest that RT genotypic diversity may influence the emergence of drug resistance...
  50. ncbi Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1
    Dan Turner
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    Antimicrob Agents Chemother 48:2993-8. 2004
    ..These substitutions and polymorphisms reflect different patterns of codon usage among viruses of different subtypes. However, the existence of different subtypes may only rarely affect patterns of drug resistance-associated mutations...
  51. ncbi The R362A mutation at the C-terminus of CA inhibits packaging of human immunodeficiency virus type 1 RNA
    Xiaofeng Guo
    McGill AIDS Centre, Lady Davis Institute-Jewish General Hospital, 3755 Cote Ste-Catherine Road, Montreal, Quebec, Canada H3T 1E2
    Virology 343:190-200. 2005
    ..These data suggest that one potential function for the C-terminal disordered sequence of CA in HIV-1 replication is to regulate HIV-1 RNA packaging...
  52. ncbi Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations
    Fernando A Frankel
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada
    AIDS 21:665-75. 2007
    ..To determine the underlying biochemical mechanisms responsible for the diminished viral replicative capacity associated with K65R/M184V-containing viruses...
  53. ncbi Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase
    Fernando A Frankel
    McGill AIDS Centre, Lady Davis Institute-Jewish General Hospital, , Montreal, Quebec H3T 1E2, Canada
    Antimicrob Agents Chemother 49:2657-64. 2005
    ..Finally, we confirmed previous findings that L74V-containing viruses display diminished replication capacity and that this is associated with reduced levels of synthesis of early reverse-transcribed viral DNA molecules...
  54. ncbi Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture
    Daniel A Donahue
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    Antimicrob Agents Chemother 54:1047-54. 2010
    ..We discuss how stage-dependent inhibition helps to explain the unique viral load decay dynamics observed clinically with RAL...
  55. ncbi The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates
    Karidia Diallo
    McGill AIDS Centre, Lady Davis Institute-Jewish General Hospital, McGill University, Montreal, H3T 1E2 Quebec, Canada
    Antimicrob Agents Chemother 47:2376-9. 2003
    ..Similarly, there was a marked delay in the emergence of mutations associated with APV resistance (I54 M/L/V) in subtype B viruses harboring M184V compared with paired WT viral isolates...
  56. ncbi Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture
    Marco Petrella
    McGill University AIDS Centre, Jewish General Hospital, Lady Davis Institute for Medical Research, 3755, , , , Canada
    Antimicrob Agents Chemother 48:4189-94. 2004
    ..In contrast, neither ddI nor ddC was able to maintain M184V to the same extent as the other drugs after 10 weeks of tissue culture in mixtures of wild-type viruses and isolates containing M184V in different proportions...
  57. ncbi Sequences downstream of the 5' splice donor site are required for both packaging and dimerization of human immunodeficiency virus type 1 RNA
    Rodney S Russell
    McGill AIDS Centre, Lady Davis Institute-Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    J Virol 77:84-96. 2003
    ..We conclude that both the SL3 motif and GA-rich RNA sequences, located downstream of the 5' splice donor site, are required for efficient RNA packaging and dimerization...
  58. ncbi Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection
    Dan Turner
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    J Acquir Immune Defic Syndr 37:1627-31. 2004
    ..05). These findings suggest that both decreased viremia and viral fitness in the case of M184V-containing HIV-1 variants may impact on viral transmissibility...
  59. ncbi Role of RNA in facilitating Gag/Gag-Pol interaction
    Ahmad Khorchid
    Lady Davis Institute for Medical Research and McGill AIDS Center Jewish General Hospital, McGill University, Montreal, Quebec, Canada H3T 1E2
    J Virol 76:4131-7. 2002
    ..When present only in Gag-Pol, this mutation has no effect upon complex formation. This result indicates that Gag-Pol may not interact directly with RNA but rather requires RNA-facilitated Gag multimerization for its interaction with Gag...
  60. ncbi Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag
    Xiaofeng Guo
    McGill AIDS Centre, Lady Davis Institute-Jewish General Hospital, 3755 Cote Ste-Catherine Rd, Montreal, Quebec, Canada H3T 1E2
    J Virol 79:1803-12. 2005
    ..Based on the myristyl switch model, we propose that the M368A mutation inhibits Gag multimerization and, as a result, restricts the binding of Gag to cellular membranes...
  61. ncbi Deletion of stem-loop 3 is compensated by second-site mutations within the Gag protein of human immunodeficiency virus type 1
    Liwei Rong
    McGill AIDS Centre, Lady Davis Institute-Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    Virology 314:221-8. 2003
    ..Therefore, the positive effects of A11V and I12V on dimerization of the SL3-deleted RNA must have taken place at the maturation stage...
  62. ncbi Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1
    Thomas A Toni
    McGill University AIDS Centre, Department of Medicine, and Lady Davis Institute, Jewish General Hospital, 3755 Cote Ste Catherine Rd, Montreal, Quebec, Canada H3T 1E2
    Antimicrob Agents Chemother 54:907-11. 2010
    ..Thirty HIV-1 subtype C- and 26 subtype B-infected patients lacking K65R as determined by conventional sequencing methods were studied, and viral minority species were found in four HIV-1 subtype C samples...
  63. ncbi The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity
    Hong Tao Xu
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    Antimicrob Agents Chemother 54:2401-8. 2010
    ....
  64. ncbi Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1
    Dimitrios Coutsinos
    McGill University AIDS Center, Jewish General Hospital, Montreal, QC, Canada
    Antivir Chem Chemother 20:117-31. 2010
    ..This new study now further establishes the basis for differential occurrence of both K65R and thymidine analogue mutations (TAMs) between subtypes...
  65. ncbi The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses
    Xin Wei
    McGill University AIDS Centre, Lady Davis Institute-Jewish General Hospital, McGill University, , , , Canada H3T 1E2
    AIDS 16:2391-8. 2002
    ..Viruses that had the A-rich-loop deleted were able to reestablish replication ability quickly in the wild-type RT, which provides further evidence for the plasticity of the HIV genome...
  66. ncbi Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations
    Maureen Oliveira
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    Antimicrob Agents Chemother 53:1683-5. 2009
    ..The original mutations were maintained by the presence of apricitabine but were lost when cultured without drug pressure...
  67. ncbi The Tat protein of human immunodeficiency virus type 1 (HIV-1) can promote placement of tRNA primer onto viral RNA and suppress later DNA polymerization in HIV-1 reverse transcription
    Masanori Kameoka
    McGill University AIDS Centre, Lady Davis Institute-Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2
    J Virol 76:3637-45. 2002
    ..We hypothesize that the second activity, illustrating functional homology between Tat and NC, suggests a potential role for NC in the displacement of Tat during viral maturation...
  68. ncbi A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors
    Bluma Brenner
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    AIDS 17:F1-5. 2003
    ..CONCLUSIONS: V106M may be a signature mutation in clade C patients treated with EFV and may have the potential to confer high-level multi-NNRTI resistance...
  69. ncbi Arginine methylation of the HIV-1 nucleocapsid protein results in its diminished function
    Cédric F Invernizzi
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, 3755 Cote Sainte Catherine Road, Montreal, Quebec, Canada
    AIDS 21:795-805. 2007
    ..As Tat is known to be asymmetrically arginine dimethylated by protein arginine methyltransferase 6 (PRMT6) in its ARM, we investigated whether NC could also act as a substrate for this enzyme...
  70. ncbi Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection
    Bluma G Brenner
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    J Virol 76:1753-61. 2002
    ..These results indicate that MDR viruses that are generated following PHI can establish persistent infections as dominant quasispecies despite their impaired replicative competence...
  71. ncbi Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1
    Karidia Diallo
    McGill University AIDS Centre, Lady Davis Institute-Jewish General Hospital, Montreal, Quebec, Canada
    Antimicrob Agents Chemother 46:2254-6. 2002
    ..These data suggest that the presence of ZDV amplifies differences in replication capacity between wild-type HIV-1 and the mutant variant...
  72. ncbi HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture
    Bluma G Brenner
    McGill University AIDS Centre, Jewish General Hospital, , Montreal, Quebec, Canada
    AIDS 20:F9-13. 2006
    ..CONCLUSION: Tenofovir -based regimens will need to be carefully monitored in subtype C infections for the possible selection of K65R...
  73. ncbi Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis
    Xin Wei
    McGill University AIDS Centre, Lady Davis Institute-Jewish General Hospital, H3T 1E2, , , Canada
    Virology 311:202-12. 2003
    ..These findings provide biochemical evidence that initiation of tRNA(Lys3)-primed DNA synthesis is an important rate-limiting step in reverse transcription that correlates with viral replication fitness...
  74. ncbi High rates of forward transmission events after acute/early HIV-1 infection
    Bluma G Brenner
    McGill AIDS Centre Jewish General Hospital, Montreal, Canada
    J Infect Dis 195:951-9. 2007
    ..A population-based phylogenetic approach was used to characterize human immunodeficiency virus (HIV)-transmission dynamics in Quebec...
  75. ncbi Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1
    Dan Turner
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec, Canada H3T 1E2
    J Antimicrob Chemother 53:53-7. 2004
    ..Interactions between different mutations may complicate the understanding of HIV drug resistance with regard to the likelihood of therapeutic success...
  76. ncbi Translation of Pr55(gag) augments packaging of human immunodeficiency virus type 1 RNA in a cis-acting manner
    Chen Liang
    McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2
    AIDS Res Hum Retroviruses 18:1117-26. 2002
    ..Taken together, our data demonstrate that cis translation of Pr55(gag) is needed for efficient packaging of HIV-1 RNA...
  77. ncbi Substitutions in the reverse transcriptase and protease genes of HIV-1 subtype B in untreated individuals and patients treated with antiretroviral drugs
    Dan Turner
    McGill University, Montreal, Quebec, Canada
    MedGenMed 7:69. 2005
    ..In conclusion, the G-->A transition was most prevalent in RT and PR among untreated patients. In contrast, A-->G was the most prevalent transition in patients treated with antiretroviral drugs...
  78. ncbi Might the M184V substitution in HIV-1 RT confer clinical benefit?
    Marco Petrella
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
    AIDS Rev 4:224-32. 2002
    ..There is a need for randomized clinical trials of this type in order to validate the potential benefit of maintenance of M184V and whether continued use of 3TC is the only means of attaining this objective...
  79. ncbi Spliced human immunodeficiency virus type 1 RNA is reverse transcribed into cDNA within infected cells
    Chen Liang
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada H3T
    AIDS Res Hum Retroviruses 20:203-11. 2004
    ..Therefore, spliced HIV-1 RNA molecules must have been reverse transcribed along with full-length viral RNA during infection...
  80. ncbi Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection
    Bluma Brenner
    McGill University AIDS Centre, Jewish General Hospital and McGill University Health Centre, Montreal, Quebec, Canada
    AIDS 18:1653-60. 2004
    ..CONCLUSIONS: Genotypic analysis in PHI may identify superinfection and MDR infections that represent important determinants of virological and treatment outcome...
  81. ncbi The M184V mutation in reverse transcriptase can delay reversion of attenuated variants of simian immunodeficiency virus
    James B Whitney
    McGill University AIDS Centre, Lady Davis Institute-Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2
    J Virol 76:8958-62. 2002
    ..We also observed that M184V significantly impaired the potential for both compensatory mutagenesis and reversion in these mutants both in cell lines and in peripheral blood mononuclear cells...
  82. ncbi Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 gag
    Chen Liang
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2
    J Virol 76:11729-37. 2002
    ..Therefore, these four mutations must have prevented Gag from generating large complexes...
  83. ncbi HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors
    Mark A Wainberg
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    J Acquir Immune Defic Syndr 34:S2-7. 2003
    ..This paper summarizes current knowledge about the mutations in the reverse transcriptase gene of HIV-1 that are responsible for drug resistance and the mechanisms whereby drug resistance develops...
  84. ncbi A structurally disordered region at the C terminus of capsid plays essential roles in multimerization and membrane binding of the gag protein of human immunodeficiency virus type 1
    Chen Liang
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    J Virol 77:1772-83. 2003
    ....
  85. ncbi HIV-1 drug resistance: can we overcome?
    Bluma G Brenner
    Lady Davis Institute for Medical Research, Jewish General Hospital, McGill AIDS Centre, 3755 Cote Ste Catherine Road, Montreal, Quebec, Canada H3T 1E2
    Expert Opin Biol Ther 2:751-61. 2002
    ..This review discusses the development and influence of known drug mutations on drug susceptibility versus viral fitness...
  86. ncbi Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal
    Jean Pierre Routy
    Immunodeficiency Service and Division of Hematology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    AIDS 18:2305-12. 2004
    ..A study of chronically infected (CI) patients, who represent potential HIV-1 transmitters, was carried out in order to ascertain biological factors associated with this trend change...
  87. ncbi Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations
    Hong Tao Xu
    McGill AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Cote Ste Catherine Rd, Montreal, Quebec H3T 1E2, Canada
    J Virol 85:11300-8. 2011
    ..Structural modeling shows that the addition of E138K to M184I/V promotes tighter dNTP binding...
  88. ncbi Transcription of preintegrated HIV-1 cDNA modulates cell surface expression of major histocompatibility complex class I via Nef
    Richard D Sloan
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, H3T 1E2 Canada
    J Virol 85:2828-36. 2011
    ..Hence, the capacity of HIV-1 to modulate MHC-I is not linked to its ability to integrate. Thus, Nef-mediated evasion of host immune responsiveness might be attributable, in part at least, to transcription from unintegrated viral DNA...
  89. ncbi Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes
    Eugene L Asahchop
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    Antimicrob Agents Chemother 55:600-7. 2011
    ..We identified K101Q, E138K, V179E, V189I, G190E, and H221Y as mutations not included among the 17 currently recognized resistance-associated mutations for ETR...
  90. ncbi Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator
    Philippe Roof
    McGill AIDS Center, McGill University, Montreal, Quebec, Canada
    Virology 296:77-83. 2002
    ..Furthermore, preliminary evidence suggests that the acetylation of subtype-specific Tat proteins may correlate with their transactivation efficiency...
  91. ncbi Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase
    Koen K A Van Rompay
    California Regional Primate Research Center, University of California, Davis, California 95616, USA
    J Virol 76:6083-92. 2002
    ..These data demonstrate that the M184V mutation in SIV conferred a slightly reduced fitness but did not affect disease outcome...
  92. ncbi Deficient dimerization of human immunodeficiency virus type 1 RNA caused by mutations of the u5 RNA sequences
    Rodney S Russell
    McGill AIDS Centre, Lady Davis Institute-Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada
    Virology 303:152-63. 2002
    ..In contrast, mutation of palindrome 5'-AAGCUU-3', which resides within R and crowns the poly(A) hairpin, did not affect either RNA dimerization or RNA packaging...
  93. ncbi Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus
    Marina B Klein
    Immunodeficiency Service, Montreal Chest Institute, Department of Medicine, McGill University Health Centre, Montreal, Quebec Canada
    AIDS 17:1001-8. 2003
    ..CONCLUSIONS: This novel triple combination has the potential to provide simultaneous activity against both HIV and hepatitis C and deserves further study to determine if can be safely administered in the clinical setting...
  94. ncbi In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1
    Serge Dandache
    Ambrilia Biopharma, Inc, 1000 Chemin du Golf, Verdun, Quebec, Canada H3E 1H4
    Antimicrob Agents Chemother 51:4036-43. 2007
    ..These data underscore the potential for PL-100 to be used in the treatment of drug-resistant HIV disease and argue for its further development...
  95. ncbi Chemoprophylaxis of HIV infection: moving forward with caution
    Robert M Grant
    J Infect Dis 194:874-6. 2006
  96. ncbi Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen
    Florence Doualla-Bell
    Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education, Gaborone
    Antimicrob Agents Chemother 50:2210-3. 2006
    ..L89I, K20T/I, and E35D polymorphic changes were also identified. These findings suggest that subtype C viruses in Botswana may develop resistance to NFV via subtype-specific pathways...
  97. ncbi Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study)
    Andrew R Zolopa
    Stanford University School of Medicine, Stanford, CA 94305 5107, USA
    Clin Infect Dis 41:92-9. 2005
    ..We sought to determine how much agreement exists within a group of experts in the interpretation of complex genotypes...
  98. ncbi A HIV-1 minimal gag protein is superior to nucleocapsid at in vitro annealing and exhibits multimerization-induced inhibition of reverse transcription
    Ariel Roldan
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    J Biol Chem 280:17488-96. 2005
    ..These results suggest that the initial stages of reverse transcription may be regulated by the multimerization of Pr55Gag polyprotein at times prior to the cleavage of NC...
  99. ncbi Generic HIV drugs--enlightened policy for global health
    Mark A Wainberg
    AIDS Centre at the Jewish General Hospital, McGill University, Montreal, USA
    N Engl J Med 352:747-50. 2005
  100. ncbi In vitro identification and characterization of an early complex linking HIV-1 genomic RNA recognition and Pr55Gag multimerization
    Ariel Roldan
    McGill University AIDS Centre, Lady Davis Institute-Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    J Biol Chem 279:39886-94. 2004
    ..We propose a model for the RNA-protein interaction, based on previous results and those presented in this study...
  101. ncbi Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance
    Joel E Gallant
    The Johns Hopkins University, Baltimore, MD, USA
    Antivir Ther 8:489-506. 2003
    ..This review summarizes research advances that further the understanding of nucleoside and nucleotide analogue resistance mutations, and their interplay...

Research Grants4

  1. DELETION MUTAGENESIS WITHIN NONCODING SEGMENTS OF HIV1
    Mark Wainberg; Fiscal Year: 2001
    ..6. To determine whether these attenuated SIV constructs may protect against subsequent challenge with virulent forms of SIV and SIV/HIV hybrids. ..